UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~December~~March 2912, ~~2017~~2018

~~AMAIZE~~CURATIVE ~~BEVERAGE~~BIOSCIENCES, ~~CORPORATION~~INC.

(exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

333-59114		33-0730042
Commission File Number		IRS Employer Identification Number

5042 Wilshire Blvd. Los Angeles, CA		90036
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (949) 287-3164

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (SEE General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 4 5.0103. ~~CHANGES~~AMENDMENTS INTO ~~REGISTRANT’S~~ARTICLES ~~CERTIFYING~~OF ~~ACCOUNTANT~~INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

On ~~December~~October 296, 2017, ~~(the~~Amaize ~~“Resignation~~Beverage ~~Date”) Pritchett~~Corporation, ~~Siler~~a ~~and~~Nevada ~~Hardy~~corporation ~~P.C.~~ (the “~~PSH~~Registrant”) ~~resigned~~filed asan ~~the~~amendment ~~independent registered~~to ~~public~~its ~~accounting~~Articles of ~~firm~~Incorporation ~~for Amaize Beverage Corporation~~ (the “~~Company~~Amendment”). Onwith ~~December 29, 2017,~~ the ~~Company engaged~~Secretary ~~Haynie~~of &State ~~Company, Salt Lake City, Utah, as its new independent registered public accounting firm. The change~~ of the ~~Company’s~~ ~~independent~~state ~~registered~~of ~~public~~Nevada ~~accounting~~providing ~~firm~~for ~~from~~a ~~PSH~~name tochange ~~Haynie & Company was approved unanimously by our~~to ~~board~~Curative ofBiosciences, ~~directors~~Inc.

~~The~~On ~~reports~~October of3, ~~PSH~~2017, on the Company’s ~~financial~~submitted ~~statements~~to ~~for~~FINRA ~~the~~an ~~two~~Issuer ~~most~~Company ~~recent~~Related ~~fiscal~~Action ~~years~~Notification ~~did~~Form ~~not~~requesting ~~contain~~a anchange ~~adverse~~of orthe ~~disclaimer~~Company’s name and symbol. The market effective date of ~~opinion~~the ~~and~~name ~~were~~change ~~not~~has ~~qualified~~been ordeclared ~~modified~~by Financial Industry Regulatory Authority as toMarch ~~uncertainty~~14, ~~audit~~2018. ~~scope,~~The orCompany’s ~~accounting~~new ~~principles~~symbol is CBDX. The Company’s new CUSIP number is 23127M101.

~~During~~ITEM ~~the~~9.01 ~~two~~FINANCIAL ~~most~~STATEMENTS ~~recent~~AND fiscal years and through the Resignation Date, there were (i) no disagreements between the Company and PSH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement, if not resolved to the satisfaction of PSH, would have caused PSH to make reference thereto in their reports on the consolidated financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-KEXHIBITS.

~~The Company~~3.3 ~~provided PSH with a copy of this Form 8-K and requested that PSH furnish it with a letter addressed~~ Amendment to the ~~Securities and~~Registrant’s ~~Exchange~~Articles ~~Commission stating whether or not PSH agrees with the above statements. A copy~~ of ~~such letter~~Incorporation, ~~dated~~filed ~~December~~on 29October 6, ~~2017,~~ ~~is attached as Exhibit 16~~2017.1.

During the Company’s two most recent fiscal years and in the subsequent interim period through the Resignation Date, the Company has not consulted with Haynie & Company regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that Haynie & Company concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).SIGNATURES

~~ITEM~~Pursuant ~~9.01~~to ~~FINANCIAL~~the ~~STATEMENTS~~requirements ~~AND~~of ~~EXHIBITS~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(d) Exhibits.

	CURATIVE BIOSCIENCES, INC.

Dated: March 13, 2018	By:	*/s/* Richard Damion
		Richard Damion Chief Executive Officer

Exhibit Number		Description
16.1		Letter from Pritchett, Siler and Hardy P.C. dated December 29, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Amaize Beverage Corporation
Dated: December 29, 2017	By:	/s/ Richard Damion
		Richard Damion Chief Executive Officer

Filing Compare · CURATIVE BIOSCIENCES, INC.